Comparison of Standard Antibiotic Treatments Versus Epidemiologically Guided Regimens in Adults with Cirrhosis and Bacterial Infections

What this Trial Is About

Researchers are comparing standard antibiotic treatments to regimens guided by epidemiological surveillance in adults with decompensated cirrhosis who have bacterial infections. This Phase 4 clinical trial aims to evaluate how these two approaches impact antibiotic resistance development and infection outcomes. The study is sponsored by Eva Bonfill and uses a randomized, parallel design. Participants are assigned to one of two groups the control group receives conventional antibiotic treatment following local hospital guidelines, while the experimental group receives antibiotic treatment guided by local guidelines combined with colonization and epidemiological surveillance. Both groups are monitored during hospitalization and up to 28 days following treatment initiation. During the study, participants will undergo assessments to track antibiotic resistance rates, colonization and infection by multidrug-resistant organisms, infection resolution, and liver-related clinical scores such as ACLF, MELD, and Child-Pugh. Researchers will also evaluate hospital stay length, ICU admission days, use of life support, rehospitalizations, antibiotic consumption, adverse events, and survival rates. Study participation lasts through hospitalization and up to 28 days post-treatment for outcome evaluation.

Trial Comparing Conventional Antibiotic Strategies Versus Regimens Guided by Epidemiological Surveillance in Infected Patients With Cirrhosis (SURVIC_STUDY)